Status:
COMPLETED
Effect of Intravenous Immunglobulin (IVIG) After Myocardial Infarction
Lead Sponsor:
Oslo University Hospital
Collaborating Sponsors:
Helse Stavanger HF
Conditions:
Acute Myocardial Infarction
Eligibility:
All Genders
18-18 years
Phase:
PHASE3
Brief Summary
The instigators hypothesize that IVIG, given in the acute phase following MI in patients at risk for developing HF, will improve cardiac performance, and by attenuating cardiac remodeling in this phas...
Detailed Description
This double-blind placebo-controlled study represents a new approach to cardiovascular disease. The project deals with unresolved issues in the intersection between cardiology, immunology and molecula...
Eligibility Criteria
Inclusion
- Age of 18-80 years
- Have a recent MI (\<5days)
- Have ASAT \>100 U/L or CKMB \> 50 U/L.
- Have LVEF \<40%.
- Are on optimal medical treatment and considered unsuitable for surgical intervention.
Exclusion
- Evidence of unstable disease, concomitant ischemia or unstable angina during the hospitalization.
- Significant concomitant disease such as infections, pulmonary disease or connective tissue disease.
- Participating in other studies.
- Inability to participate.
- Diseases that require surgery.
- Planned revascularisation.
- Known hypersensitivity to IVIG.
Key Trial Info
Start Date :
February 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2010
Estimated Enrollment :
62 Patients enrolled
Trial Details
Trial ID
NCT00430885
Start Date
February 1 2007
End Date
May 1 2010
Last Update
January 27 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rikshospitalet University Hospital
Oslo, Norway